Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M S, Carlino"'
Autor:
S. Piperno-Neumann, M. S. Carlino, V. Boni, D. Loirat, F. M. Speetjens, J. J. Park, E. Calvo, R. D. Carvajal, M. Nyakas, J. Gonzalez-Maffe, X. Zhu, M. D. Shirley, T. Ramkumar, A. Fessehatsion, H. E. Burks, P. Yerramilli-Rao, E. Kapiteijn
Publikováno v:
British Journal of Cancer, 128, 1040-1051. SPRINGERNATURE
Background Up to 50% of patients with uveal melanoma develop metastases (MUM) with a poor prognosis and median overall survival of approximately 1 year. Methods This phase I study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc13a7b6997fe71f8832691ca2f3966f
http://hdl.handle.net/1887/3566795
http://hdl.handle.net/1887/3566795
Autor:
F, Dimitriou, K, Namikawa, I L M, Reijers, E I, Buchbinder, J A, Soon, A, Zaremba, P, Teterycz, M J, Mooradian, E, Armstrong, Y, Nakamura, M G, Vitale, L E, Tran, X, Bai, C, Allayous, S, Provent-Roy, A, Indini, P, Bhave, M, Farid, K C, Kähler, I, Mehmi, V, Atkinson, O, Klein, C J, Stonesifer, F, Zaman, A, Haydon, R D, Carvajal, O, Hamid, R, Dummer, A, Hauschild, M S, Carlino, M, Mandala, C, Robert, C, Lebbe, J, Guo, D B, Johnson, P A, Ascierto, A N, Shoushtari, R J, Sullivan, B, Cybulska-Stopa, P, Rutkowski, L, Zimmer, S, Sandhu, C U, Blank, S N, Lo, A M, Menzies, G V, Long
Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) are limited. We determined the efficacy of ICIs in MM, analyzed by primary site and ethnicity/race.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc56111b83de57d0e398a5cc2f06c3a3
https://www.ncbi.nlm.nih.gov/pubmed/35716907
https://www.ncbi.nlm.nih.gov/pubmed/35716907
Autor:
T, Lam, M M K, Chan, A N, Sweeting, S M C, De Sousa, A, Clements, M S, Carlino, G V, Long, K, Tonks, E, Chua, R F, Kefford, D R, Chipps
Publikováno v:
Internal medicine journal. 45(10)
Ipilimumab (Yervoy; Bristol-Myers Squibb) is a novel fully humanised monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4, an immune checkpoint molecule, to augment anti-tumour T-cell responses. It is associated with significant immune-re